BROADWOOD PARTNERS, L.P. 4
4 · Insight Molecular Diagnostics Inc. · Filed Feb 12, 2026
Research Summary
AI-generated summary of this filing
IMDX 10% Owner Broadwood Partners Buys $3.0M Stock
What Happened
Broadwood Partners, L.P. (reported as a 10% owner) purchased 521,739 shares of Insight Molecular Diagnostics, Inc. (IMDX) common stock on February 10, 2026. The shares were acquired in a registered direct offering at $5.75 per share for a total purchase price of $2,999,999. This transaction is coded "P" for purchase.
Key Details
- Transaction date: 2026-02-10; filing date (Form 4): 2026-02-12 — filed timely (within the SEC’s two-business-day window).
- Price and size: 521,739 shares at $5.75 each = $2,999,999 total.
- Shares owned after the transaction: not specified in the filing.
- Important footnotes:
- F1: Shares are directly owned by Broadwood Partners; may be deemed beneficially owned by Broadwood Capital, Inc. (general partner) and Neal C. Bradsher (president of Broadwood Capital). Each disclaims beneficial ownership except to the extent of pecuniary interest.
- F3: Purchase was made under a Securities Purchase Agreement as a registered direct offering.
- F4: Filing notes certain warrants are currently exercisable (not part of this reported common-share purchase).
Context
This is an institutional purchase by a reported 10% owner rather than an individual executive. Purchases by large shareholders can be seen as an investment vote of confidence, but the filing itself is purely factual and does not state motivation.
Insider Transaction Report
- Purchase
Common Stock, no par value
[F3][F1]2026-02-10$5.75/sh+521,739$2,999,999→ 11,931,839 total - Purchase
Common Stock, no par value
[F3][F1]2026-02-10+0→ 11,931,839 total(indirect: Footnote)
- 157
Common Stock, no par value
[F2] - 150,093
Warrant to Purchase Common Stock
[F4][F1]Exercise: $30.60Exp: 2027-04-19→ Common Stock (150,093 underlying) - 150,093(indirect: See Footnote)
Warrant to Purchase Common Stock
[F4][F1]Exercise: $30.60Exp: 2027-04-19→ Common Stock (150,093 underlying)
Footnotes (4)
- [F1]The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F2]These securities are directly owned by Neal C. Bradsher.
- [F3]On February 10, 2026, Broadwood Partners entered into a Securities Purchase Agreement with Insight Molecular Diagnostics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 521,739 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in a registered direct offering for a total purchase price of $2,999,999, or $5.75 per Common Share.
- [F4]These warrants are currently exercisable.